In 2013, the U.S. Supreme Court invalidated a specific patent on gene testing for an isolated strand of DNA, which is thought to be linked to hereditary breast cancer. The invalidation of the patent, held by Myriad Genetics, meant that the company no longer had a monopoly on this method of cancer detection, and the […]

Read More →